Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
0.0%
operating margin TTM
0.0%
revenue TTM
1.55 Million
revenue per share TTM
2.11$
valuation ratios | |
|---|---|
| pe ratio | -0.18 |
| peg ratio | 0.00 |
| price to book ratio | -0.66 |
| price to sales ratio | 0.00 |
| enterprise value multiple | -0.25 |
| price fair value | -0.66 |
profitability ratios | |
|---|---|
| gross profit margin | 0.0% |
| operating profit margin | 0.0% |
| pretax profit margin | 0.0% |
| net profit margin | 0.0% |
| return on assets | -340.29% |
| return on equity | 261.41% |
| return on capital employed | 312.74% |
liquidity ratio | |
|---|---|
| current ratio | 0.52 |
| quick ratio | 0.52 |
| cash ratio | 0.09 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 532.45 |
| cash conversion cycle | -532.45 |
| receivables turnover | 0.00 |
| payables turnover | 0.69 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.62 |
| debt equity ratio | -0.67 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | -2.03 |
| interest coverage | -6.41 |
| cash flow to debt ratio | -6.78 |
cash flow ratios | |
|---|---|
| free cash flow per share | -25.47 |
| cash per share | 1.02 |
| operating cash flow per share | -25.47 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -6.78 |
| short term coverage ratios | -6.78 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time Qualigen Therapeutics, Inc. (NASDAQ:QLGN) reported earnings?
Qualigen Therapeutics, Inc. (QLGN) published its most recent earnings results on 14-11-2024.
What is Qualigen Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Qualigen Therapeutics, Inc. (NASDAQ:QLGN)'s trailing twelve months ROE is 261.41%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Qualigen Therapeutics, Inc. (QLGN) currently has a ROA of -340.29%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did QLGN's net profit margin stand at?
QLGN reported a profit margin of 0.0% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is QLGN's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 0.52 in the most recent quarter. The quick ratio stood at 0.52, with a Debt/Eq ratio of -0.67.